Histogenics provides NeoCart® phase 3 clinical trial enrollment update
Histogenics announced that as of Oct. 24, 2016 it had enrolled 183, or approximately three-quarters, of the 245 patients required to complete enrollment of its ongoing NeoCart Phase 3 clinical trial. This trial is being conducted under a Special Protocol Assessment with the FDA. October 24, 2016